We hypothesise that using an anti‐CD6 antibody in COVID‐19 patients could reduce the concentration of several pro‐inflammatory cytokines, including IL‐6, IFN‐γ and IL‐17, representing an advantage as compared to single‐cytokine targeting antibodies. Here, IL17A is linked to COVID-19.